https://www.selleckchem.com/pr....oducts/phorbol-12-my
Background We aimed to assess the effectiveness and cost of patients with first line tyrosine kinase inhibitors (TKIs) sequence of first (1G) and second generation (2G) followed by osimertinib. Materials methods Using the French nationwide claims and hospitalization database, we analyzed non-small-cell lung cancer patients who had been treated with osimertinib between April 2015 and December 2017, after a first line treatment with a TKI-1G/2G. Results The median time on treatment for sequential TKI-1G/2G fo
Like
Comment
Share
